The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

The economic burden of obesity is also significant. In the Finger Lakes, excess medical spending due to obesity is estimated ...